Intervention Review

You have free access to this content

Anticonvulsants for alcohol dependence

  1. Pier Paolo Pani1,*,
  2. Emanuela Trogu1,
  3. Matteo Pacini2,
  4. Icro Maremmani3

Editorial Group: Cochrane Drugs and Alcohol Group

Published Online: 13 FEB 2014

Assessed as up-to-date: 19 DEC 2013

DOI: 10.1002/14651858.CD008544.pub2


How to Cite

Pani PP, Trogu E, Pacini M, Maremmani I. Anticonvulsants for alcohol dependence. Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD008544. DOI: 10.1002/14651858.CD008544.pub2.

Author Information

  1. 1

    Health District 8 (ASL 8) Cagliari, Social-Health Division, Cagliari, Sardinia, Italy

  2. 2

    European Addiction Treatment Association (Europad), Policlinico Umberto I, University La Sapienza, Rome, Rome, Italy

  3. 3

    "Santa Chiara" University Hospital, University of Pisa, Italy, "Vincent P. Dole" Dual Diagnosis Unit, Department of Neurosciences, Pisa, Italy

*Pier Paolo Pani, Social-Health Division, Health District 8 (ASL 8) Cagliari, Via Logudoro 17, Cagliari, Sardinia, 09127, Italy. pallolo@tin.it.

Publication History

  1. Publication Status: New
  2. Published Online: 13 FEB 2014

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 4]
Figure 4. Forest plot of comparison: 1 Anticonvulsants versus placebo, outcome: 1.1 Dropouts.
[Figure 5]
Figure 5. Forest plot of comparison: 1 Anticonvulsants versus placebo, outcome: 1.3 Alcohol use, continuous outcome: drinks/drinking day.
[Figure 6]
Figure 6. Forest plot of comparison: 1 Anticonvulsants versus placebo, outcome: 1.4 Alcohol use, continuous outcome: heavy drinking.
[Figure 7]
Figure 7. Forest plot of comparison: 1 Anticonvulsants versus placebo, outcome: 1.5 Continuous abstinence, dichotomous outcome.
[Figure 8]
Figure 8. Forest plot of comparison: 1 Anticonvulsants versus placebo, outcome: 1.6 Abstinence, continuous outcome.
[Figure 9]
Figure 9. Forest plot of comparison: 1 Anticonvulsants versus placebo, outcome: 1.7 Adverse events.
[Figure 10]
Figure 10. Funnel plot of comparison: 1 Anticonvulsants versus placebo, outcome: 1.1 Dropouts.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Anticonvulsants versus placebo, Outcome 1 Dropouts.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Anticonvulsants versus placebo, Outcome 2 Heavy drinking, dichotomous outcome.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Anticonvulsants versus placebo, Outcome 3 Alcohol use, continuous outcome: drinks/drinking day.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Anticonvulsants versus placebo, Outcome 4 Alcohol use, continuous outcome: heavy drinking.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Anticonvulsants versus placebo, Outcome 5 Continuous abstinence, dichotomous outcome.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Anticonvulsants versus placebo, Outcome 6 Abstinence, continuous outcome.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Anticonvulsants versus placebo, Outcome 7 Adverse events.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Anticonvulsants versus placebo, Outcome 8 Craving (OCDS total score or analogue scale).
[Analysis 1.9]
Analysis 1.9. Comparison 1 Anticonvulsants versus placebo, Outcome 9 Liver enzyme levels (GGT).
[Analysis 2.1]
Analysis 2.1. Comparison 2 Specific anticonvulsants versus placebo, Outcome 1 Dropouts.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Specific anticonvulsants versus placebo, Outcome 2 Heavy drinking, dichotomous outcome: valproate.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Specific anticonvulsants versus placebo, Outcome 3 Alcohol use, continuous outcome: drinks/drinking day.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Specific anticonvulsants versus placebo, Outcome 4 Alcohol use, continuous outcome: heavy drinking.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Specific anticonvulsants versus placebo, Outcome 5 Abstinence, continuous outcome.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Specific anticonvulsants versus placebo, Outcome 6 Continuous abstinence, dichotomous outcome.
[Analysis 2.7]
Analysis 2.7. Comparison 2 Specific anticonvulsants versus placebo, Outcome 7 Adverse events.
[Analysis 2.8]
Analysis 2.8. Comparison 2 Specific anticonvulsants versus placebo, Outcome 8 Craving (OCDS total score or analogue scale).
[Analysis 2.9]
Analysis 2.9. Comparison 2 Specific anticonvulsants versus placebo, Outcome 9 Liver enzyme levels.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Anticonvulsants versus placebo according to length of trial, Outcome 1 Dropouts.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Anticonvulsants versus placebo according to length of trial, Outcome 2 Heavy drinking, dichotomous outcome: over six weeks.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Anticonvulsants versus placebo according to length of trial, Outcome 3 Alcohol use, continuous outcome: drinks/drinking day.
[Analysis 3.4]
Analysis 3.4. Comparison 3 Anticonvulsants versus placebo according to length of trial, Outcome 4 Alcohol use, continuous outcome: heavy drinking.
[Analysis 3.5]
Analysis 3.5. Comparison 3 Anticonvulsants versus placebo according to length of trial, Outcome 5 Continuous abstinence, dichotomous outcome.
[Analysis 3.6]
Analysis 3.6. Comparison 3 Anticonvulsants versus placebo according to length of trial, Outcome 6 Abstinence, continuous outcome.
[Analysis 3.7]
Analysis 3.7. Comparison 3 Anticonvulsants versus placebo according to length of trial, Outcome 7 Adverse events.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Anticonvulsants versus placebo according to psychosocial interventions, Outcome 1 Dropouts.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Anticonvulsants versus placebo according to psychosocial interventions, Outcome 2 Heavy drinking, dichotomous outcome: associated psychotherapy.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Anticonvulsants versus placebo according to psychosocial interventions, Outcome 3 Alcohol use, continuous outcome: drinks/drinking day.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Anticonvulsants versus placebo according to psychosocial interventions, Outcome 4 Alcohol use, continuous outcome: heavy drinking.
[Analysis 4.5]
Analysis 4.5. Comparison 4 Anticonvulsants versus placebo according to psychosocial interventions, Outcome 5 Continuous abstinence, dichotomous outcome.
[Analysis 4.6]
Analysis 4.6. Comparison 4 Anticonvulsants versus placebo according to psychosocial interventions, Outcome 6 Abstinence, continuous outcome, days abstinent (%): associated psychotherapy.
[Analysis 4.7]
Analysis 4.7. Comparison 4 Anticonvulsants versus placebo according to psychosocial interventions, Outcome 7 Adverse events.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Anticonvulsants versus placebo according to psychiatric co-morbidity, Outcome 1 Dropouts.
[Analysis 5.2]
Analysis 5.2. Comparison 5 Anticonvulsants versus placebo according to psychiatric co-morbidity, Outcome 2 Heavy drinking, dichotomous outcome.
[Analysis 5.3]
Analysis 5.3. Comparison 5 Anticonvulsants versus placebo according to psychiatric co-morbidity, Outcome 3 Alcohol use, continuous outcome: drinks/drinking day.
[Analysis 5.4]
Analysis 5.4. Comparison 5 Anticonvulsants versus placebo according to psychiatric co-morbidity, Outcome 4 Alcohol use, continuous outcome: heavy drinking.
[Analysis 5.5]
Analysis 5.5. Comparison 5 Anticonvulsants versus placebo according to psychiatric co-morbidity, Outcome 5 Continuous abstinence, dichotomous outcome.
[Analysis 5.6]
Analysis 5.6. Comparison 5 Anticonvulsants versus placebo according to psychiatric co-morbidity, Outcome 6 Abstinence, continuous outcome.
[Analysis 5.7]
Analysis 5.7. Comparison 5 Anticonvulsants versus placebo according to psychiatric co-morbidity, Outcome 7 Adverse events.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Anticonvulsants versus other medications (naltrexone), Outcome 1 Dropouts.
[Analysis 6.2]
Analysis 6.2. Comparison 6 Anticonvulsants versus other medications (naltrexone), Outcome 2 Severe relapse, dichotomous outcome.
[Analysis 6.3]
Analysis 6.3. Comparison 6 Anticonvulsants versus other medications (naltrexone), Outcome 3 Number of heavy drinking days.
[Analysis 6.4]
Analysis 6.4. Comparison 6 Anticonvulsants versus other medications (naltrexone), Outcome 4 Continuous abstinence, dichotomous outcome.
[Analysis 6.5]
Analysis 6.5. Comparison 6 Anticonvulsants versus other medications (naltrexone), Outcome 5 Abstinence continuous outcome: days to severe relapse.
[Analysis 6.6]
Analysis 6.6. Comparison 6 Anticonvulsants versus other medications (naltrexone), Outcome 6 Adverse events.
[Analysis 6.7]
Analysis 6.7. Comparison 6 Anticonvulsants versus other medications (naltrexone), Outcome 7 Craving (OCDS total score).
[Analysis 6.8]
Analysis 6.8. Comparison 6 Anticonvulsants versus other medications (naltrexone), Outcome 8 Liver enzyme levels (GGT).
[Analysis 7.1]
Analysis 7.1. Comparison 7 Specific anticonvulsants (topiramate) versus specific other medications (naltrexone), Outcome 1 Dropouts.
[Analysis 7.2]
Analysis 7.2. Comparison 7 Specific anticonvulsants (topiramate) versus specific other medications (naltrexone), Outcome 2 Severe relapse, dichotomous outcome.
[Analysis 7.3]
Analysis 7.3. Comparison 7 Specific anticonvulsants (topiramate) versus specific other medications (naltrexone), Outcome 3 Continuous abstinence, dichotomous outcome.
[Analysis 7.4]
Analysis 7.4. Comparison 7 Specific anticonvulsants (topiramate) versus specific other medications (naltrexone), Outcome 4 Craving (OCDS total score).
[Analysis 8.1]
Analysis 8.1. Comparison 8 Anticonvulsants versus no medication, Outcome 1 Alcohol use dichotomous: relapse.
[Analysis 8.2]
Analysis 8.2. Comparison 8 Anticonvulsants versus no medication, Outcome 2 Mood.
[Analysis 8.3]
Analysis 8.3. Comparison 8 Anticonvulsants versus no medication, Outcome 3 Craving (OCDS score).